MorphoSys is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates. MorphoSys is listed on the Frankfurt Stock Exchange and NASDAQ under the symbol MOR. Headquartered in Planegg near Munich, Germany and the MorphoSys group includs the fully owned U.S. subsidiary MorphoSys US Inc. based in Boston, MA.